Advertise on podcast: PharmOncology

Daraxonrasib may be less effective in certain RAS mutations. FDA review: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/220910Orig1s000TOC.html Preclinical daraxonrasib studies: https://pubs.acs.org/jmcmar/article-abstract/68/6/6064/3643788/Discovery-of-Daraxonrasib-RMC-6236-a-Potent-and https://pmc.ncbi.nlm.nih.gov/articles/PMC11149917/ Analysis of common KRAS mutations including GTPase activity: https://aacrjournals.org/mcr/article/13/9/1325/89607/Biochemical-and-Structural-Analysis-of-Common Resistance mechanisms to daraxonrasib: https://aacrjournals.org/cancerres/article/85/8_Supplement_2/LB281/761862/Abstract-LB281-Mechanisms-of-resistance-to-the-RAS

Why tucatinib had a black box warning for hepatotoxicity added New FDA indication approval: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-trastuzumab-and-pertuzumab-maintenance-treatment-her2-positive-breast-cancer

ADCs may not increase the therapeutic window Cancer Cell commentary: https://www.cell.com/cancer-cell/fulltext/S1535-6108(22)00445-7

Using myeloma as an example, why trial representativeness has a meaningful clinical impact in oncology DETERMINATION trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2204925 Blood letter: https://ashpublications.org/blood/article/137/21/2987/475530/Incidence-of-skin-hyperpigmentation-in-Black

A story of two antibody drug conjugate payloads

How I think agents should be sequenced in HER2 mutant lung cancer. Case report on zongertinib upregulating HER2 receptors: https://pmc.ncbi.nlm.nih.gov/articles/PMC12964209/

Why did we start using an anti-seizure medication for ICANS? Study on levetiracetam: https://ashpublications.org/bloodadvances/article/9/21/5501/546533/Routine-prophylaxis-with-levetiracetam-offers-no

Thoughts on the HER2 3+ and HER2 2+/ISH+ subgroups for zanidatamab, and its mechanism of action JACOB trial: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30481-9/abstract INNOVATION trial: https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.LBA331 HERIZON-GEA-01: https://www.nejm.org/doi/full/10.1056/NEJMoa2517729 Zanidatamab preclinical study: https://pmc.ncbi.nlm.nih.gov/articles/PMC10011572/N

How ESR1 mutations develop in breast cancer, targeting them, and some differences between elacestrant, imlunestrant, and vepdegestrant

Explaining CELMoDs. It's hard to pronounce ubiquitination! JCO article on VTE events in clinical trials: https://ascopubs.org/doi/10.1200/JCO-25-00489

With lurbinectedin being withdrawn from second line extensive stage small cell lung cancer, thoughts on what treatments have been effective in this aggressive cancer.

Problems with how we currently test for HER2 and possible future directions. Trastuzumab in endometrial cancer: https://pmc.ncbi.nlm.nih.gov/articles/PMC8792803/Issues with HER2 testing in endometrial cancer: https://www.gynecologiconcology-online.net/article/S0090-8258(25)01072-8/fulltext https://www.mdpi.com/2072-6694/18/12/2009Novel methods of testing for HER2: https://www.nature.com/articles/s41698-026-01365-6

Podcast on the changing definition of chemotherapy resistance French small cell lung cancer trial: https://pubmed.ncbi.nlm.nih.gov/32888454/ Platinum resistance in endometrial cancer (Japan): https://pmc.ncbi.nlm.nih.gov/articles/PMC12346239/ 1989 article showing 10% response rates to platinum in platinum resistant ovarian cancer: https://www.nature.com/articles/bjc1989132 Platinum resistant patients may still respond to platinum: https://pubmed.ncbi.nlm.nih.gov/29807697/

Thoughts on the FDA's recent approval of gedatolisib https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gedatolisib-fulvestrant-or-without-palbociclib-hr-positive-her2-negative-locally

Thoughts on all the NCCN preferred second-line DLBCL regimens, other than CAR-T and transplant